The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Open accessAbstract
BACKGROUND: Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal activity. To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35). METHODS: In this phase 1, open-label, multicenter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma. Patients had received a median of three previous chemotherapy regimens (range, one to seven), and 73% had undergone autologous stem-cell transplantation. RESULTS: The maximum tolerated dose was 1.8 mg per kilogram, administered every 3 weeks. Objective responses, including 11 complete remissions, were observed in 17 patients. Of 12 patients who received the 1.8-mg-per-kilogram dose, 6 (50%) had an objective response. The median duration of response was at least 9.7 months. Tumor regression was observed in 36 of 42 patients who could be evaluated (86%). The most common adverse events were fatigue, pyrexia, diarrhea, nausea, neutropenia, and peripheral neuropathy. CONCLUSIONS: Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study. Treatment was associated primarily with grade 1 or 2 (mild-to-moderate) toxic effects. (Funded by Seattle Genetics; ClinicalTrials.gov number, NCT00430846.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.-K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022473 · Cited by 838
Dürkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B., & Stein, H. (1992) · Cell · doi:10.1016/0092-8674(92)90180-k · Cited by 643
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Falini, B., Pileri, S., Pizzolo, G., Durkop, H., Flenghi, L., Stirpe, F., Martelli, M., & Stein, H. (1995) · Blood · doi:10.1182/blood.v85.1.1.bloodjournal8511 · Cited by 441
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Sun, M. M. C., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., & Alley, S. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050201y · Cited by 370
High Expression of the CC Chemokine TARC in Reed-Sternberg Cells
van den Berg, A., Visser, L., & Poppema, S. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65424-7 · Cited by 367
Ansell, S. M., Horwitz, S. M., Engert, A., Khan, K. D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8972 · Cited by 251
Forero‐Torres, A., Leonard, J. P., Younes, A., Rosenblatt, J. D., Brice, P., Bartlett, N. L., Bosly, A., Pinter‐Brown, L., Kennedy, D., Sievers, E. L., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07740.x · Cited by 249
Self-citationEngineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
Sureda, A., Constans, M., Iriondo, A., Arranz, R., Caballero, M. D., Vidal, M. J., Petit, J., López, A., Lahuerta, J. J., Carreras, E., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi119 · Cited by 220
Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
Swain, S. M., & Arezzo, J. C. (2008) · PubMed · Cited by 142
Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22
Niens, M., Visser, L., Nolte, I. M., van der Steege, G., Diepstra, A., Cordano, P., Jarrett, R. F., Meerman, G. J. T., Poppema, S., & van den Berg, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06964.x · Cited by 129
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Ré, D., Thomas, R. K., Behringer, K., & Diehl, V. (2005) · Blood · doi:10.1182/blood-2004-12-4750 · Cited by 116
Weihrauch, M. R., Manzke, O., Beyer, M., Haverkamp, H., Diehl, V., Bohlen, H., Wolf, J., & Schultze, J. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0100 · Cited by 110
Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma ≤ 1 cm Is Not Justified
Sarnaik, A. A., Zager, J. S., Cox, L. E., Ochoa, T. M., Messina, J. L., & Sondak, V. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9937 · Cited by 86
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
Younes, A. (2009) · Hematology · doi:10.1182/asheducation-2009.1.507 · Cited by 65
Self-citation
Cited by
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Self-citationPro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Self-citation
Metadata
- Authors
- Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-11-04
- Volume
- 363
- Issue
- 19
- Pages
- 1812-1821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2011118089
- Cited by
- 1,368
- References
- 22
- FWCI
- 69.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.